Skip to main content
SpringerLink
Log in

Prostate cancer, screening, and prostate-specific antigen

Promise or peril?

  • Clinical Review
  • Published:
Journal of General Internal Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Centers for Disease Control. Trends in prostate cancer—United States, 1980–1988. MMWR. 1992;41:401–4.

    Google Scholar 

  2. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med. 1993;118:793–803.

    PubMed  CAS  Google Scholar 

  3. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics 1994. CA Cancer J Clin. 1994;44:7–26.

    PubMed  CAS  Google Scholar 

  4. Horm JW, Sondik EJ. Person-years of life lost due to cancer in the United States, 1970 and 1984. Am J Public Health. 1989;79:1490–3.

    PubMed  CAS  Google Scholar 

  5. Muir CS, Nectoux, J. Staszewski J. The epidemiology of prostate cancer. Acta Oncol. 1991;30:133–40.

    PubMed  CAS  Google Scholar 

  6. Gittes RF. Carcinoma of the prostate. N Engl J Med. 1991;324:236–45.

    Article  PubMed  CAS  Google Scholar 

  7. Optenberg SA, Thompson IM. Economics of screening for carcinoma of the prostate. Urol Clin North Am. 1990;17:719–37.

    PubMed  CAS  Google Scholar 

  8. Hoel DG, Davis DL, Miller AB, Sondik EJ, Swerdlow AJ. Trends in cancer mortality in 15 industrialized countries, 1969–1986. J Natl Cancer Inst. 1992;84:313–20.

    Article  PubMed  CAS  Google Scholar 

  9. Meikle AW, Smith JH Jr. Epidemiology of prostate cancer. Urol Clin North Am. 1990;17:709–18.

    PubMed  CAS  Google Scholar 

  10. Smith PH. The case for no initial treatment of localized prostate cancer. Urol Clin North Am. 1990;17:827–34.

    PubMed  CAS  Google Scholar 

  11. Gerber GS, Chodak GW. Digital rectal examination in the early detection of prostate cancer. Urol Clin North Am. 1990;17: 739–44.

    PubMed  CAS  Google Scholar 

  12. Garnick MB. Prostate cancer: screening, diagnosis, and management. Ann Intern Med. 1993;118:804–18.

    PubMed  CAS  Google Scholar 

  13. Scardino PJ. Early detection of prostate cancer. Urol Clin North Am. 1989;16:635–55.

    PubMed  CAS  Google Scholar 

  14. Stamey TA. Diagnosis of prostate cancer: a personal view. J Urol. 1992;147:830–2.

    PubMed  CAS  Google Scholar 

  15. Murphy GP, Natarajan N, Pontes JE, et al. The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol. 1982;127:928–34.

    PubMed  CAS  Google Scholar 

  16. Stamey TA, McNeal JE. Adenocarcinoma of the prostate. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED Jr. (eds). Campbell’s Urology. Philadelphia: W. B. Saunders, 1992;1159–221.

    Google Scholar 

  17. Littrup PJ, Lee F, Mettlin C. Prostate cancer screening: current trends and future implications. CA Cancer J Clin. 1992;42:198–210.

    PubMed  CAS  Google Scholar 

  18. Whitmore WF, Warner JA, Thompson IM. Expectant management of prostate cancer. Cancer. 1991;67:1091–6.

    Article  PubMed  Google Scholar 

  19. Johansson JE, Adami HO, Andersson SO, et al. High 10-year survival rate in patients with early, untreated prostate cancer. JAMA. 1992;267:2191–6.

    Article  PubMed  CAS  Google Scholar 

  20. Adolfsson J, Cartstensen J, Lowhagen T. Deferred treatment in clinically localised prostatic carcinoma. Br J Urol. 1992;69:183–7.

    PubMed  CAS  Google Scholar 

  21. Fleming C, Wasson J, Albertson PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA. 1993;269:2650–8.

    Article  PubMed  CAS  Google Scholar 

  22. George NJR. Natural history of prostate cancer managed by conservative therapy alone. Lancet. 1988;i:494–6.

    Article  Google Scholar 

  23. Handley R, Carr TW, Travis D, Powell PH, Hall RR. Deferred treatment for prostate cancer. Br J Urol. 1988;62:249–53.

    Article  PubMed  CAS  Google Scholar 

  24. Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy. JAMA. 1993;269:2633–6.

    Article  PubMed  CAS  Google Scholar 

  25. Lowe BA, Listrom MB. Incidental carcinoma of the prostate: an analysis of the predictors of progression. J Urol. 1988;140:1340–3.

    PubMed  CAS  Google Scholar 

  26. Brown ML, Potosky AL, Thompson GB, Kessler LG. The knowledge and use of screening tests for colorectal and prostate cancer: data from the National Health Interview Survey. Prev Med. 1990;19:562–74.

    Article  PubMed  CAS  Google Scholar 

  27. Mold JW, Holtgrave DR, Bisonno RS, Marley DS, Wright RA, Spann SJ. The evaluation and treatment of men with asymptomatic prostatic nodules in primary care: a decision analysis. J Fam Pract. 1992;34:561–8.

    PubMed  CAS  Google Scholar 

  28. Gerber GS, Thompson IM, Thisted R, Chodak GW. Disease-specific survival following routine prostate cancer screening by digital rectal examination. JAMA. 1993;269:61–4.

    Article  PubMed  CAS  Google Scholar 

  29. American Cancer Society. Guidelines for cancer-related checkup: recommendations and rationale. CA Cancer J Clin. 1980;30:194–240.

    Google Scholar 

  30. National Cancer Institute. Working guidelines for early cancer detection. Rationale and supporting evidence to decrease mortality. Bethesda, MD: National Cancer Institute, 1987.

    Google Scholar 

  31. Fisher M (ed). Screening for prostate cancer. In: U.S. Preventive Services Task Force. Guide to clinical preventive services: an assessment of the effectiveness of 169 interventions. Baltimore, MD: Williams & Wilkins, 1989;63–6.

    Google Scholar 

  32. Canadian Task Force on Periodic Health Examination. The periodic health examination. Can Med Assoc J. 1979;121:1194–254.

    Google Scholar 

  33. Labrie F, Dupont A, Suburu S, et al. Serum prostate specific antigen as prescreening test for prostate cancer. J Urol. 1992;147:846–52.

    PubMed  CAS  Google Scholar 

  34. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostate carcinoma with prostate specific antigen. J Urol. 1992;147:841–5.

    PubMed  CAS  Google Scholar 

  35. Mettlin C, Lee F, Drago J, Murphy GP. American Cancer Society national prostate cancer detection project. Cancer. 1991;67:2949–58.

    Article  PubMed  CAS  Google Scholar 

  36. Drago JR, York JP. Prostate specific antigen, digital rectal examination and transrectal ultrasound in predicting the probability of cancer. J Surg Oncol. 1992;49:172–5.

    Article  PubMed  CAS  Google Scholar 

  37. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156–61.

    Article  PubMed  CAS  Google Scholar 

  38. Gustafsson O, Norming U, Almgard L, et al. Diagnostic methods in the detection of prostate cancer: a study of a randomly selected population of 2,400 men. J Urol 1992;148:1827–31.

    PubMed  CAS  Google Scholar 

  39. Wasson J, Fleming C, Bruskewitz R, et al. The treatment of localized prostate cancer: what are we doing, what do we know, and what should we be doing? Semin Urol. 1993;11:23–6.

    PubMed  CAS  Google Scholar 

  40. Madsen PO, Graversen PH, Gasser TC, Corle DK. Treatment of localised prostate cancer. Radical prostatectomy versus placebo. A fifteen year followup. Scand J Urol. Mephrol Suppl. 1988;110:95–100.

    CAS  Google Scholar 

  41. Cooner WH, Mosley BR, Rutherford CL Jr, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol. 1990;143:1146–52.

    PubMed  CAS  Google Scholar 

  42. Whitmore WJ Jr. Natural history of low stage prostatic cancer and the impact of early detection. Urol Clin North Am. 1990;17:689–97.

    PubMed  Google Scholar 

  43. Naughton D. Researchers weigh pros and cons of PSA screening. Rep Med Guidelines Outcomes Res. 1993;4:1–6.

    Google Scholar 

  44. Littrup PJ, Goodman AC, Mettlin CJ. The benefit and cost of prostate cancer early detection. CA Cancer J Clin. 1993;43:134–49.

    PubMed  CAS  Google Scholar 

  45. Benson MC, Whang IS, Pantuck A, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. 1992;147:815–6.

    PubMed  CAS  Google Scholar 

  46. Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol. 1992;147:817–21.

    PubMed  CAS  Google Scholar 

  47. Brawer MK, Aramburu EAG, Chen GI, Preston SD, Ellis WJ. The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma. J Urol. 1993;150:369–73.

    PubMed  CAS  Google Scholar 

  48. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992;267:2215–20.

    Article  PubMed  CAS  Google Scholar 

  49. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. JAMA. 1993;270:860–4.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. John D. Voss MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Received from the Department of Health Care Sciences, George Washington University Medical Center, 2150 Pennsylvania Avenue, NW, Washington, DC 20037.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Voss, J.D. Prostate cancer, screening, and prostate-specific antigen. J Gen Intern Med 9, 468–474 (1994). https://doi.org/10.1007/BF02599070

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02599070

Keywords

Search

Navigation